Por favor, use este identificador para citar o enlazar este ítem: http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/8254
The molecular reach of antibodies determines their SARS-CoV-2 neutralisation potency
Anna Huhn
Daniel Nissley
Daniel Wilson
Mikhail Kutuzov
Róbert Donát
Tiong Kit Tan
Michael Barton
Chang Liu
wanwisa dejnirattisai
Piyada Supasa
Juthathip Mongkolsapaya
Alain Townsend
william james
Gavin Screaton
Philip Anton van der Merwe
Charlotte Deane
Samuel Isaacson
Omer Dushek
Acceso Abierto
Atribución-NoComercial-SinDerivadas
https://doi.org/10.1101/2023.09.06.556503
https://www.biorxiv.org/content/10.1101/2023.09.06.556503v1
Antibodies play crucial roles in health and disease and are invaluable tools for diagnostics, research, and therapy. Although antibodies bind bivalently, we lack methods to analyse bivalent binding. Here, we introduce a particle-based model and use it to analyse bivalent binding of SARS-CoV-2 RBD-specific antibodies in surface plasmon resonance assays. The method reproduces the monovalent on/off-rates and enables measurements of new parameters, including the molecular reach, which is the maximum antigen separation that supports bivalent binding. We show that the molecular reach (22-46 nm) exceeds the physical size of an antibody (15 nm) and that the variation in reach across 45 patient-isolated antibodies is the best correlate of viral neutralisation. Using the complete set of fitted parameters, the model predicts an emergent antibody binding potency that equals the neutralisation potency. This novel analytical method should improve our understanding and exploitation of antibodies and other bivalent molecules.
bioRxiv
07-09-2023
Preimpreso
Inglés
Público en general
VIRUS RESPIRATORIOS
Aparece en las colecciones: Materiales de Consulta y Comunicados Técnicos

Cargar archivos: